Recently, new approaches and methodologies (NAMs) are expected to use human relevant models for drug development to predict the effects of drugs in humans more accurately. In vitro, in silico, and machine learning are considered as NAMs in terms of 3Rs principles. It is expected that cutting-edge innovations would be considered in drug screening and efficacy/safety assessment.
We have developed a new platform to detect cardiotoxicities, such as contractility dysfunction and cell damage, using iPSC-cardiomyocytes and performed an international validation study with international agencies.
Here we would like to share our international collaboration using iPSC-cardiomyocytes and discuss future perspectives.